16.27

2.11% -0.35

Viridian Therapeutics Inc (VRDN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$16.62

Aprire:

$16.81

Volume 24 ore:

839.42K

Relative Volume:

0.65

Capitalizzazione di mercato:

$1.29B

Reddito:

$288.00K

Utile/perdita netta:

$-228.06M

Rapporto P/E:

-3.8282

EPS:

-4.25

Flusso di cassa netto:

$-168.82M

1 W Prestazione:

-0.79%

1M Prestazione:

-11.62%

6M Prestazione:

+4.43%

1 anno Prestazione:

-12.15%

Intervallo 1D:

$16.25

$16.97

Intervallo di 1 settimana:

$15.62

$16.97

Portata 52W:

$11.40

$27.20

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Nome

Viridian Therapeutics Inc

Settore

Healthcare (1169)

Industria

Biotechnology (678)

Telefono

617.272.4600

Indirizzo

221 CRESCENT STREET, WALTHAM

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-11

Ultimi documenti SEC

VRDN's Discussions on Twitter

Confronta VRDN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VRDN Viridian Therapeutics Inc	16.27	1.29B	288.00K	-228.06M	-168.82M	-4.25
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-19	Downgrade	Wells Fargo	Overweight → Equal Weight
2024-11-25	Iniziato	TD Cowen	Buy
2024-09-11	Reiterato	Needham	Buy
2024-06-11	Iniziato	Wolfe Research	Outperform
2024-06-06	Iniziato	Goldman	Buy
2024-05-09	Downgrade	B. Riley Securities	Buy → Neutral
2024-05-09	Downgrade	Ladenburg Thalmann	Buy → Neutral
2023-06-14	Iniziato	BTIG Research	Buy
2023-06-14	Ripresa	Credit Suisse	Outperform
2023-05-30	Iniziato	RBC Capital Mkts	Outperform
2023-04-17	Iniziato	Wells Fargo	Overweight
2023-03-30	Iniziato	Stifel	Buy
2022-12-19	Iniziato	Cowen	Outperform
2022-12-19	Iniziato	Needham	Buy
2022-12-16	Iniziato	Credit Suisse	Outperform
2022-12-01	Iniziato	H.C. Wainwright	Buy
2022-06-23	Iniziato	B. Riley Securities	Buy
2021-11-18	Iniziato	SVB Leerink	Outperform
2021-10-12	Iniziato	Evercore ISI	Outperform
2021-01-25	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie

Feb 21, 2025

Viridian Therapeutics (VRDN) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

Feb 21, 2025

Feb 20, 2025

Where are the Opportunities in (VRDN) - Stock Traders Daily

Feb 20, 2025

Feb 19, 2025

What Do Wall Street Analysts Think About Viridian Therapeutics Inc (NASDAQ: VRDN) Stock? - Stocks Register

Feb 19, 2025

Rice Hall James & Associates LLC Takes Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat

Feb 19, 2025

Feb 17, 2025

Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5%Should You Sell? - MarketBeat

Feb 17, 2025

Feb 12, 2025

Viridian Therapeutics Inc (NASDAQ: VRDN): Slumped -0.56% In 2025, Outlook Stable - Stocks Register

Feb 12, 2025

Feb 11, 2025

Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 5.8% – Should You Sell? - Armenian Reporter

Feb 07, 2025

VRDN Stock Sees Decline of Approximately -7.82% in Last Five Days - Knox Daily

Feb 07, 2025

Feb 06, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Feb 06, 2025

Viridian's Strategic Expansion: 527,750 Share Options Awarded as TED Programs Advance - StockTitan

Feb 06, 2025

Feb 05, 2025

Analyzing Ratios: Viridian Therapeutics Inc (VRDN)’s Financial Story Unveiled - The Dwinnex

Feb 05, 2025